Dr. Laura Niklason, M.D., Ph.D., Senior Scientific Advisor
Dr. Laura Niklason, the Company's scientific founder, is a world leader in tissue engineering. Her research has appeared in some of the most highly regarded peer-reviewed scientific publications, including the journals Science and The Lancet. Dr. Niklason is currently Associate Professor of Anesthesia and Biomedical Engineering at Yale University. Dr. Niklason received her PhD in Biophysics from the University of Chicago and her MD from the University of Michigan. She performed her postdoctoral work at MIT in Dr. Robert Langer's laboratory.

Carrie Cox, CEO
Ms. Cox most recently served as Executive Vice President and President, Global Pharmaceuticals, at Schering-Plough Corporation, from 2003 until its merger with Merck & Co., Inc., in November 2009. In that role, she was responsible for the company's global prescription pharmaceutical business, which generated approximately $16 billion in annual sales, with a five year CAGR of 22%. Prior to that, she held a similar role as President, Global Prescription Business at Pharmacia Corporation. Previously, Cox served as SVP of Global Business Management at Pharmacia & Upjohn (the predecessor company to Pharmacia), and as VP of Women's Healthcare at Wyeth-Ayerst. Cox spent her early career at Sandoz pharmaceuticals (now Novartis) in a variety of commercial roles of increasing responsibility.

Cox currently serves on the Boards of Directors of Texas Instruments, Cardinal Health and Celgene. Cox has been named six times to FORTUNE Magazine's list of the "50 Most Powerful Women in Business." Her work has been featured in the Harvard Business Review and in the New York Times bestseller, The Profit Zone. She received her B.S. from Massachusetts College of Pharmacy, and worked for several years in retail and hospital pharmacy.

Paul Boyer, Chief Financial Officer
Recognized for his proven financial and operational expertise in growing and managing private and public technology companies, Mr. Boyer spent the past 25 years as a CFO and or COO of private and public companies from start-up to $700M in revenues. Mr. Boyer has executed over $375M in public, private equity/debt & venture financings, including a successful IPO, 16 M&A transactions and 2 successful turnarounds.

Paul Boyer is currently the Founder & President of FinOps Solutions, an executive finance and operations services firm focused on providing "fractional" CFO & COO Services, Transaction Support, M&A Advisory and Turnaround Management to start-up, early-stage, turnaround, high growth and VC/private equity ventures.

David J McQuillan, Ph.D., Chief Scientific Officer
Dr. McQuillan brings over 25 years of leadership experience in tissue engineering, extracellular matrix biology, and biological scaffold research, development, and commercialization. He was previously Senior Vice President at Kinetic Concepts Inc. (KCI) where he established and led the Center for Advanced Research and Technology. He joined KCI with the acquisition of LifeCell Corporation in 2008 where he had served since 1999 first as Vice President of Research, and most recently Vice President of Research and Development. At LifeCell, David led the research and development of market-leading biologic scaffolds for tissue regeneration. Prior to joining LifeCell Corporation, he was a faculty member in the center for Extracellular Matrix Biology, Texas A&M University. David holds BSc and PhD degrees in Biochemistry from Monash University, Australia and pursued post-doctoral training at the National Institutes of Health, Bethesda, MD.

Alison Pilgrim, BM, BCh, Dphil., Chief Medical Officer
Over the last decade Alison has worked with small public and VC backed biotechnology companies including Elan, Avera, CoLucid and BioVascular. As CMO she has led multiple virtual development programs. She has also advised start-up companies and venture capital funds on drug development. In her first industry position as a clinical pharmacologist she ran a range of Phase I studies including first-in-man, pharmacokinetics and efficacy modeling in healthy subjects. She then led the global clinical trials program for Imitrex from phase II to IV and as Director of the Cardiovascular, Metabolic and CNS therapeutic group at Glaxo supervised the clinical development of drugs for migraine, diabetes, stroke, anesthesia, psychiatry and heart disease. At Sanofi she led the clinical interactions with the FDA and EMEA for Plavix, achieving rapid marketing approval for the desired broad indication. At DuPont Pharmaceuticals Alison led clinical development activities across all therapeutic areas including CNS, CVS, Inflammation, oncology and HIV as well as strengthening and integrating the European capability of the organization. She initiated an extensive redesign initiative spanning clinical operations, project team management and strategic planning which generated major improvements in the speed and efficiency of clinical research. She received her medical degrees and doctorate in developmental biology from Oxford University.

Bill Tente, MS, VP of Manufacturing and Regulatory Affairs
Mr. Tente joined Humacyte in 2008. He has over 24 years of experience in product and bioprocess development for a variety of cell therapy and tissue-engineered products and biologics. He was the Vice President of Operations for Neurotech USA from 2002 to 2007. Neurotech USA has developed encapsulated cell technology products for the long term delivery of therapeutic protein factors to the back of the eye to treat chronic diseases of the retina. Prior to joining Neurotech USA, he was the Director of Operations of Chimeric Therapies, Inc. and was responsible for manufacturing, quality control and logistics for bone marrow processing and transplantation operations. Previously, he was the Director of Clinical Production at CytoTherapeutics, Inc., where he was responsible for biological process development, manufacturing and quality control for the encapsulated pain cell therapy product. He has also held managerial and research positions in process development and production of cell-culture-based recombinant pharmaceuticals at the Ares Serono Group, Charles River Biotechnical Services and Schering Biotechnology. Bill holds Bachelor and Master of Sciences degrees in cell biology and microbiology from the University of Rhode Island and studied at the W. Alton Jones Cell Sciences Center in Lake Placid, NY. He has been a member of the USP Expert Committee on Gene Therapy, Cell Therapy, and Tissue Engineering since 1997 and is currently the Chairman of this committee.

Juliana Blum, Ph.D., Co-Founder and Senior Director of Business Operations
Dr. Blum has spent the past several years in the field of biomedical engineering and currently serves as Senior Director of Business Operations at Humacyte. Blum oversees Humacyte's day to day operational activities and leads the company's key external collaborations. She is responsible for developing, executing, and managing the company's tissue supply chain. In this role, Blum combines her molecular biology expertise with tissue engineering to aid in improving the technologies surrounding Humacyte's vascular graft and therapeutic filler products. Blum received her doctorate in Molecular Biology from Loyola University in Chicago, with a focus in gene therapy and cardiovascular disease, and her B.S. degree from Carthage College in Wisconsin.

Shannon Dahl, Ph.D., Co-Founder and Senior Director of Scientific Operations
Dr. Dahl has been working in the field of tissue engineering since 1998, and currently serves as Senior Director of Scientific Operations at Humacyte. Dahl has been instrumental in leading in vivo testing of Humacyte's tissue engineered vascular grafts, working closely with surgical collaborators as well as with the Food and Drug Administration (FDA) for design of pre-clinical studies. She has advanced manufacturing practices for production of tissue engineered products and defined relevant vitro tests for quality release of tissue engineered products. Dahl received her S.B. from the Massachusetts Institute of Technology, where she performed research in conjunction with Harvard Medical School. She received her Ph.D. from Duke University.